Skip to main content
SAM CHUN DANG PHARM CO. LTD logo

SAM CHUN DANG PHARM CO. LTD — Investor Relations & Filings

Ticker · 000250 ISIN · KR7000250001 KO Manufacturing
Open in API
Filings indexed 224 across all filing types
Latest filing 2025-06-30 Regulatory Filings
Country KR South Korea
Listing KO 000250

About SAM CHUN DANG PHARM CO. LTD

http://www.scd.co.kr/english/scd/index.…

SAM CHUN DANG PHARM CO. LTD. is a pharmaceutical company focused on the development, manufacturing, and sale of medications. The company specializes in ophthalmic products, establishing itself as a significant player in the generic eye care market. Its portfolio also extends to other therapeutic areas, including antibiotics and medications for the circulatory system. The company produces a range of ethical (prescription) and over-the-counter (OTC) drugs in both sterile and non-sterile forms. Manufacturing operations adhere to international quality standards, holding both US and EU Good Manufacturing Practice (GMP) certifications.

Recent filings

Filing Released Lang Actions
[기재정정]단일판매ㆍ공급계약체결(자율공시)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system, specifically a 'Correction Report' (정정신고) regarding a 'Single Sale/Supply Contract' (단일판매ㆍ공급계약체결). It details changes to contract dates and milestones for a supply agreement with Glenmark Pharmaceuticals. Since this is a specific regulatory disclosure of a material business contract and does not fit into the other specialized categories like M&A or financial reports, it is classified as a general Regulatory Filing (RNS).
2025-06-30 Korean
임원ㆍ주요주주특정증권등거래계획보고서
Director's Dealing Classification · 100% confidence The document is an '임원ㆍ주요주주 특정증권등 거래계획보고서' (Report on Trading Plan for Specific Securities by Executives and Major Shareholders) filed by Samchundang Pharm. This document details a planned transaction (specifically a gift of shares) by an executive/major shareholder. In the context of financial filings, reports regarding insider share transactions, including planned future transactions, are classified under 'Director's Dealing' (DIRS) as they pertain to the trading activities of company insiders.
2025-06-24 Korean
임원ㆍ주요주주특정증권등거래계획보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Trading Plan for Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주특정증권등거래계획보고서) filed by an executive (Jeon In-Seok) of Samchundang Pharm. This is a regulatory filing required by the Financial Services Commission and the Korea Exchange regarding planned transactions (in this case, a gift of shares). While it involves an executive, it is a formal regulatory disclosure of a trading plan rather than a simple 'Director's Dealing' (which usually reports completed trades) or a general 'Regulatory Filing'. Given the specific nature of the filing regarding insider trading plans, it falls under the category of Regulatory Filings (RNS) as it is a mandatory disclosure to the exchange.
2025-06-24 Korean
주주총회소집결의 (임시주주총회)
AGM Information Classification · 98% confidence The document is a formal notice of an Extraordinary General Meeting (EGM) for Samchundang Pharm, detailing the date, location, and agenda items (appointment of directors and approval of remuneration). This type of document is a standard proxy solicitation or notice of meeting, which falls under the Proxy Solicitation & Information Statement category.
2025-06-10 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement from Samchundang Pharm regarding the setting of a record date for an upcoming Extraordinary General Meeting of shareholders. It does not contain the full proxy materials or the meeting presentation itself, but rather serves as a formal notice of the record date for shareholder rights. Given its nature as a regulatory disclosure regarding corporate governance and meeting preparation, it fits best under the general regulatory filing category.
2025-06-10 Korean
분기보고서 (2025.03)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Samchundang Pharm Co., Ltd. for the period of January 1, 2025, to March 31, 2025. It contains detailed financial information, business operations, production data, and management discussions, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2025
2025-05-15 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.